{"title": "In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein", "doi": "10.1101/2020.03.10.985499", "citation_id": "2020.03.10.985499v2", "date": "2020-03-13", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.10.985499", "abstract": "<p>It is of special significance to find a safe and effective vaccine against coronavirus disease 2019 (COVID-19) that can induce T cell and B cell -mediated immune responses.  There is currently no vaccine to prevent COVID-19. In this project, a novel multi-epitope vaccine for COVID-19 virus based on surface glycoprotein was designed through application of bioinformatics methods. At the first, seventeen potent linear B-cell and T-cell binding epitopes from surface glycoprotein were predicted in silico, then the epitopes were joined together via different linkers. The ability of the selected epitopes to induce interferon-gamma was evaluate using IFNepitope web server.  One final vaccine was constructed which composed of 398 amino acids and attached to 50S ribosomal protein L7/L12 as adjuvant. Physicochemical properties, as well as antigenicity in the proposed vaccines, were checked for defining the vaccine stability and its ability to induce cell-mediated immune responses. Three-dimensional structure of the mentioned vaccine was subjected to the molecular docking studies with MHC-I and MHC-II molecules. The results proposed that the multi-epitope vaccine with 50S ribosomal protein L7/L12 was a stable construct with high aliphatic content and high antigenicity.</p>", "twitter_description": "It is of special significance to find a safe and effective vaccine against coronavirus disease 2019 (COVID-19) that can induce T cell and B cell -mediated immune responses. There is currently no vaccine to prevent COVID-19. In this project, a novel multi-epitope vaccine for COVID-19 virus based on surface glycoprotein was designed through application of bioinformatics methods. At the first, seventeen potent linear B-cell and T-cell binding epitopes from surface glycoprotein were predicted in silico, then the epitopes were joined together via different linkers. The ability of the selected epitopes to induce interferon-gamma was evaluate using IFNepitope web server. One final vaccine was constructed which composed of 398 amino acids and attached to 50S ribosomal protein L7/L12 as adjuvant. Physicochemical properties, as well as antigenicity in the proposed vaccines, were checked for defining the vaccine stability and its ability to induce cell-mediated immune responses. Three-dimensional structure of the mentioned vaccine was subjected to the molecular docking studies with MHC-I and MHC-II molecules. The results proposed that the multi-epitope vaccine with 50S ribosomal protein L7/L12 was a stable construct with high aliphatic content and high antigenicity.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.10.985499v2.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.10.985499v2", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.10.985499v2.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/13/2020.03.10.985499.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.10.985499v2", "access_rights": "restricted", "authors": ["Mandana Behbahani"]}